Directorate Change

RNS Number : 1391B

GlaxoSmithKline PLC

14 June 2016

 

GlaxoSmithKline plc (the "Company")

Executive Director Change

GSK today announces that Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017. The Board supports Dr Slaoui's decision and has agreed he will retire on 30 June 2017.

Dr Slaoui will remain a member of the Board until 31 March 2017. From 1 April 2017 until his retirement on 30 June 2017, he will serve as an advisor to both GSK and the Board. Dr Slaoui joined GSK in 1988 and the Board in 2006.

Philip Hampton, Chairman, GSK, said: "On behalf of the Board, I would like to thank Moncef for his great contribution to the company. He has been personally involved in the discovery and development of some of our most innovative vaccines and spearheaded the overhaul of GSK's pharmaceutical R&D. GSK has been fortunate to benefit from Moncef's considerable scientific and technical experience over many years and I'm pleased that during his remaining time, he will continue to provide this valuable expertise to the Company."

V A Whyte

Company Secretary

14 June 2016

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GSK enquiries:
UK Media enquiries:	David Mawdsley	[phone]	(London)
	Simon Steel	[phone]	(London)
US Media enquiries:	Sarah Alspach	[phone]	(Washington, DC)
	Sarah Spencer	[phone]	(Philadelphia)
	Jenni Ligday	[phone]	(Washington, DC)
Analyst/Investor enquiries:	Ziba Shamsi	[phone]	(London)
	Tom Curry	+ 1 215 751 5419	(Philadelphia)
	Gary Davies	[phone]	(London)
	James Dodwell	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.

Registered in England & Wales: No. 3888792

Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

END

 

 

BOAKMGMVLDNGVZG